Mustafa Saad Siddiqui

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9476658/publications.pdf

Version: 2024-02-01

28 papers 2,342 citations

16 h-index 27 g-index

29 all docs 29 docs citations

times ranked

29

2913 citing authors

#	Article	IF	CITATIONS
1	Comprehensive Evaluation of Voice-Specific Outcomes in Patients With Essential Tremor Before and After Deep Brain Stimulation. Journal of Voice, 2022, 36, 838-846.	1.5	3
2	Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel. Journal of Parkinson's Disease, 2022, 12, 917-926.	2.8	9
3	Comparative Effectiveness of Carbidopa–Levodopa Enteral Suspension and Deep Brain Stimulation on Parkinson's Disease-Related Pill Burden Reduction in Advanced Parkinson's Disease: A Retrospective Real-World Cohort Study. Neurology and Therapy, 2022, 11, 851-861.	3.2	5
4	<scp>DUOGLOBE</scp> : Oneâ€Year Outcomes in a <scp>Realâ€World</scp> Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 1061-1074.	1.5	22
5	North American survey on impact of the COVID-19 pandemic shutdown on DBS care. Parkinsonism and Related Disorders, 2021, 92, 41-45.	2.2	8
6	Auditory-Perceptual Evaluation of Deep Brain Stimulation on Voice and Speech in Patients With Dystonia. Journal of Voice, 2020, 34, 636-644.	1.5	2
7	A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies. Clinical Parkinsonism & Related Disorders, 2020, 2, 25-34.	0.9	2
8	Application of the â€~5-2-1' screening criteria in advanced Parkinson's disease: interim analysis of DUOGLOBE. Neurodegenerative Disease Management, 2020, 10, 309-323.	2.2	33
9	Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson's disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study. Lancet Neurology, The, 2020, 19, 491-501.	10.2	88
10	Analysis of the prevalence and onset of dysphonia and dysphagia symptoms in movement disorders at an academic medical center. Journal of Clinical Neuroscience, 2019, 64, 111-115.	1.5	12
11	Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease. JCI Insight, 2017, 2, e90133.	5.0	74
12	Association between subthalamic nucleus deep brain stimulation and weight gain: Results of a case–control study. Clinical Neurology and Neurosurgery, 2016, 140, 38-42.	1.4	16
13	Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa. Hypertension, 2015, 65, 101-107.	2.7	125
14	Influence of Type 2 Diabetes on Brain Volumes and Changes in Brain Volumes. Diabetes Care, 2013, 36, 90-97.	8.6	113
15	Smile and laughter induction and intraoperative predictors of response to deep brain stimulation for obsessive-compulsive disorder. Neurolmage, 2011, 54, S247-S255.	4.2	72
16	AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurology, The, 2011, 10, 309-319.	10.2	582
17	Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A doubleâ€blind, randomized, placeboâ€controlled study (RECOVER). Movement Disorders, 2011, 26, 90-99.	3.9	394
18	Weight change following deep brain stimulation for movement disorders. Journal of Neurology, 2010, 257, 1293-1297.	3.6	41

#	Article	lF	CITATIONS
19	Pseudobulbar affect: prevalence and quality of life impact in movement disorders. Journal of Neurology, 2010, 257, 1382-1387.	3.6	41
20	A Case of Mania following Deep Brain Stimulation for Obsessive Compulsive Disorder. Stereotactic and Functional Neurosurgery, 2010, 88, 322-328.	1.5	66
21	Brain penetration effects of microelectrodes and deep brain stimulation leads in ventral intermediate nucleus stimulation for essential tremor. Journal of Neurosurgery, 2010, 112, 491-496.	1.6	51
22	Inappropriate crying and laughing in Parkinson disease and movement disorders. World Journal of Biological Psychiatry, 2009, 10, 234-240.	2.6	36
23	Deep brain stimulation: Treating neurological and psychiatric disorders by modulating brain activity. NeuroRehabilitation, 2008, 23, 105-113.	1.3	6
24	Deep Brain Stimulation: Patient Selection in Parkinson's Disease, Other Movement Disorders, and Neuropsychiatric Disorders., 2008, , 83-98.		O
25	Deep brain stimulation: treating neurological and psychiatric disorders by modulating brain activity. NeuroRehabilitation, 2008, 23, 105-13.	1.3	1
26	Prognostic Significance of Hypernatremia and Hyponatremia among Patients with Aneurysmal Subarachnoid Hemorrhage. Neurosurgery, 2002, 50, 749-756.	1.1	215
27	Aggressive Mechanical Clot Disruption and Low-dose Intra-arterial Third-generation Thrombolytic Agent for Ischemic Stroke: A Prospective Study. Neurosurgery, 2002, 51, 1319-1329.	1.1	196
28	Intracerebral Hemorrhages Associated With Neurointerventional Procedures Using a Combination of Antithrombotic Agents Including Abciximab. Stroke, 2002, 33, 1916-1919.	2.0	129